Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SPHK2 | Q9NRA0 | 5/20 | 0.46 |
| ▸ | SPHK1 | Q9NYA1 | 5/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29843966 | 1.00 | L3MBTL1 (0.46) | L3MBTL1NPC1RAB9AMAPK1TDP1 | |
| SCHEMBL23578423 | 0.86 | SPHK1 (0.54) | L3MBTL1NPC1RAB9ATDP1SPHK2 | |
| SCHEMBL23588068 | 0.86 | SPHK2 (0.42) | L3MBTL1NPC1RAB9AMAPK1TDP1 | |
| SCHEMBL23588257 | 0.83 | SPHK1 (0.58) | L3MBTL1NPC1RAB9ATDP1SPHK2 | |
| SCHEMBL29844170 | 0.83 | LMNA (0.40) | L3MBTL1MAPK1TDP1KMT2ATSHR | |
| SCHEMBL23578099 | 0.83 | LMNA (0.40) | L3MBTL1MAPK1TDP1KMT2ATSHR | |
| SCHEMBL2094536 | 0.77 | PPARA (0.55) | L3MBTL1NPC1RAB9AMAPK1TDP1 | |
| SCHEMBL23894440 | 0.77 | L3MBTL1 (0.54) | L3MBTL1NPC1RAB9AMAPK1TDP1 | |
| SCHEMBL23578433 | 0.76 | ACACB (0.57) | L3MBTL1NPC1RAB9ATDP1SMN1; SMN2 | |
| SCHEMBL26691057 | 0.76 | TSHR (0.52) | L3MBTL1NPC1RAB9AMAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | SITRYX THERAPEUTICS LIMITED (GB) | 2023-07-13 | — | — | US | disclosed |
| CN-115066418-A | Carboxy derivatives with anti-inflammatory properties | 西特瑞治疗有限公司 | 2022-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219907-A1 | CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES | CPA2, RO60, C5AR1 | L3MBTL1 3425/4885NPC1 4019/4885RAB9A 1795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.